EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

Inclusion Criteria:

* Male and female subjects ≥18 years of age
* Signed written informed consent
* Histologically or cytologically documented metastatic or locally advanced survivin-expressing solid tumor for which no established therapy exists
* Disease must be measurable by RECIST criteria or evaluable by clinical, radiographic, or laboratory criteria established for the given tumor entity
* Expressing at least one of the following HLA alleles:HLA-A1,-A2,-A3,-A24, and -B7 assessed by HLAgenotyping
* ECOG performance status of ≤1, estimated life expectancy of at least 3 months
* Adequate hematological function defined by WBC ≥3 x 10x9/L, lymphocyte count ≥0.5 x 10x9/L, hemoglobin ≥10 g/dL, platelet count ≥100 x 10x9/L
* Adequate blood coagulation parameters defined as aPTT and INR ≤ 1.5 x ULN
* Adequate renal function defined by a serum creatinine ≤2 x ULN
* Adequate hepatic function defined by total bilirubin ≤2 x ULN and AST and ALT levels ≤2.5 x ULN (in subjects with liver metastases ≤5 x ULN)
* Effective contraception for female and male subjects if the risk of conception exists

Exclusion Criteria:

* Treatment in another clinical study within the past 30 days prior to the first administration of study treatment
* Previous treatment with an investigational anticancer vaccine
* Requirement of concurrent treatment with a nonpermitted drug
* Active significant autoimmune disease (with the exception of vitiligo)
* Receipt of allogeneic stem cell transplantation
* Significant acute or chronic infections (e.g. viral hepatitis, HIV)
* Primary brain tumors and brain metastases (with the exception of brain metastases that are stable after irradiation or surgically resected brain metastases if subjects have been asymptomatic for ≥6 months)
* Rapidly progressive disease (e.g. tumor lysis syndrome)
* Radiotherapy, chemotherapy, surgery (excluding prior diagnostic biopsy), immunotherapy or any investigational drug within 30 days before the start of study treatment
* Pregnancy or lactation
* Active drug or alcohol abuse
* Known hypersensitivity to the study treatment or any of its components
* Any significant disease that, in the Investigator's opinion, should exclude the subject from the study; for questions about this criterion, the Investigator should contact the sponsor.
* Persisting toxicity related to prior therapy ≥grade 2 National Cancer Institute-Common Terminology Criteria For Adverse Events version 3.0
* Legal incapacity or limited legal capacity